Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.8
2.7
Journals
Brain Sciences
Special Issues
Stem Cell Therapy in Neurodegenerative Diseases
share announcement

Stem Cell Therapy in Neurodegenerative Diseases

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Molecular and Cellular Neuroscience".

Deadline for manuscript submissions: closed (10 July 2020) | Viewed by 8942

Special Issue Editors

Dr. Julien Rossignol

E-Mail Website
Guest Editor
Neuroscience Program and College of Medicine, Central Michigan University, Mount Pleasant, MI, USA
Interests: stem cells; Huntington’s disease; stroke; dendrimers; nanoparticles; glioblastoma
Dr. Gary Dunbar

E-Mail Website
Guest Editor
1. Neuroscience Program and College of Liberal Arts and Social Scineces, Central Michigan University, Mount Pleasant, MI 48859, USA
2. Field Neuroscienes Institue, Saginaw, MI 48604 , USA
Interests: stem cells; Huntington’s disease; glioblastoma
Dr. Bhairavi Srinageshwar

E-Mail Website
Guest Editor
Neuroscience Program and College of Medicine, Central Michigan University, Mount Pleasant, MI, United States
Interests: gene and drug delivery, Huntington’s disease, Stroke, Glioblastoma

Special Issue Information

Dear Colleagues,

Stem cells are some of the most commonly used types of cells as a potential therapy for various diseases, especially for neurodegenerative diseases. Though there are different types of stem cells available, some of the most used stem cells for neurodegenerative diseases include mesenchymal stem cells, neural stem cells and induced pluripotent stem cells. These stem cells render their therapeutic effects either by secreting trophic factors to support the brain cells or can undergo site-specific differentiation to replace the dying neurons. The outcomes from various studies are very encouraging and show the enormous potential of the stem cells as a treatment option. Not only this, many studies have focused on the origin of stem cells and their respective treatment option for specific diseases. Mesenchymal stem cells are used for many decades now and is one of the few cell types that has entered the clinical trials for treating brain related diseases. The interest of using stem cells has only been appreciating among researchers due to their promising outcomes.

We invite investigators to contribute either original article(s) or review(s) to this special issue of “Stem Cell Therapy in Neurodegenerative Diseases”. The aim of this issue is to broaden the knowledge on the use of various types of stem cells for neurodegenerative diseases.

Dr. Julien Rossignol
Dr. Gary Dunbar
Dr. Bhairavi Srinageshwar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Stem cells
  • Neurodegeneration
  • Differentiation
  • Cellular, Molecular Pathways
  • Transplantation
  • Disease models
  • Behavior and cognition

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

14 pages, 2165 KiB  
Article
Exploratory Analysis of iPSCS-Derived Neuronal Cells as Predictors of Diagnosis and Treatment of Alzheimer Disease
by Eugenio Cavalli, Giuseppe Battaglia, Maria Sofia Basile, Valeria Bruno, Maria Cristina Petralia, Salvo Danilo Lombardo, Manuela Pennisi, Reni Kalfin, Lyubka Tancheva, Paolo Fagone, Ferdinando Nicoletti and Katia Mangano
Brain Sci. 2020, 10(3), 166; https://doi.org/10.3390/brainsci10030166 - 13 Mar 2020
Cited by 14 | Viewed by 4550
Abstract
Alzheimer’s disease (AD) represents the most common neurodegenerative disorder, with 47 million affected people worldwide. Current treatment strategies are aimed at reducing the symptoms and do slow down the progression of the disease, but inevitably fail in the long-term. Induced pluripotent stem cells [...] Read more.
Alzheimer’s disease (AD) represents the most common neurodegenerative disorder, with 47 million affected people worldwide. Current treatment strategies are aimed at reducing the symptoms and do slow down the progression of the disease, but inevitably fail in the long-term. Induced pluripotent stem cells (iPSCs)-derived neuronal cells from AD patients have proven to be a reliable model for AD pathogenesis. Here, we have conducted an in silico analysis aimed at identifying pathogenic gene-expression profiles and novel drug candidates. The GSE117589 microarray dataset was used for the identification of Differentially Expressed Genes (DEGs) between iPSC-derived neuronal progenitor (NP) cells and neurons from AD patients and healthy donors. The Discriminant Analysis Module (DAM) algorithm was used for the identification of biomarkers of disease. Drugs with anti-signature gene perturbation profiles were identified using the L1000FWD software. DAM analysis was used to identify a list of potential biomarkers among the DEGs, able to discriminate AD patients from healthy people. Finally, anti-signature perturbation analysis identified potential anti-AD drugs. This study set the basis for the investigation of potential novel pharmacological strategies for AD. Furthermore, a subset of genes for the early diagnosis of AD is proposed. Full article
(This article belongs to the Special Issue Stem Cell Therapy in Neurodegenerative Diseases)
►▼ Show Figures

Figure 1

Other

Jump to: Research

10 pages, 240 KiB  
Perspective
Efficacy of Cell-Based Therapies for Traumatic Brain Injuries
by Matthew R. Chrostek, Emily G. Fellows, Winston L. Guo, William J. Swanson, Andrew T. Crane, Maxim C. Cheeran, Walter C. Low and Andrew W. Grande
Brain Sci. 2019, 9(10), 270; https://doi.org/10.3390/brainsci9100270 - 10 Oct 2019
Cited by 10 | Viewed by 3919
Abstract
Traumatic brain injuries (TBIs) are a leading cause of death and disability. Additionally, growing evidence suggests a link between TBI-induced neuroinflammation and neurodegenerative disorders. Treatments for TBI patients are limited, largely focused on rehabilitation therapy, and ultimately, fail to provide long-term neuroprotective or [...] Read more.
Traumatic brain injuries (TBIs) are a leading cause of death and disability. Additionally, growing evidence suggests a link between TBI-induced neuroinflammation and neurodegenerative disorders. Treatments for TBI patients are limited, largely focused on rehabilitation therapy, and ultimately, fail to provide long-term neuroprotective or neurorestorative benefits. Because of the prevalence of TBI and lack of viable treatments, new therapies are needed which can promote neurological recovery. Cell-based treatments are a promising avenue because of their potential to provide multiple therapeutic benefits. Cell-based therapies can promote neuroprotection via modulation of inflammation and promote neurorestoration via induction of angiogenesis and neurogenesis. Neural stem/progenitor cell transplantations have been investigated in preclinical TBI models for their ability to directly contribute to neuroregeneration, form neural-like cells, and improve recovery. Mesenchymal stem cells (MSCs) have been investigated in clinical trials through multiple different routes of administration. Intravenous administration of MSCs appears most promising, demonstrating a robust safety profile, correlation with neurological improvements, and reductions in systemic inflammation following TBI. While still preliminary, evidence suggests cell-based therapies may become a viable treatment for TBI based on their ability to promote neuroregeneration and reduce inflammation. Full article
(This article belongs to the Special Issue Stem Cell Therapy in Neurodegenerative Diseases)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop